A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-01

Study Completion Date

2017-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer

NCT00074295

Lung Cancer

TERMINATED PHASE2

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy

NCT00534209

Lung Cancer

TERMINATED PHASE1/PHASE2

Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer

NCT00850785

Non Small Cell Lung Cancer

COMPLETED PHASE1

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

NCT00420732

Carcinoma, Non-Small-Cell Lung

TERMINATED PHASE2

AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer

NCT03371485

Advanced Non-small Cell Lung Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary

\- to determine the safety, toxicity, and Maximum Tolerated Dose (MTD) of autologous dendritic cell-adenovirus chemokine (C-C motif) ligand 21 (CCL21) vaccine administered as an intratumoral injection in treating patients with stage IIIB, IV, or recurrent non-small cell lung cancer

Secondary

* to determine the biologic and clinical responses to therapy
* to determine treatment-related toxicity using the NCI Common Toxicity Criteria
* to identify the maximum tolerated dose (MTD)
* to monitor patients for evidence of autologous dendritic cell-adenovirus CCL21 vaccine-induced cytokines and antigen-specific immune responses
* to detect immune responses to tumor-associated antigens and vector
* to assess patients for objective signs of tumor regression (RECIST criteria)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer (NSCLC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

No masking

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling

Group Type EXPERIMENTAL

autologous dendritic cell adenovirus CCL21 vaccine

Intervention Type BIOLOGICAL

Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

autologous dendritic cell adenovirus CCL21 vaccine

Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

10-000039, UCLA-NCI 7888, 03-06-008

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Screening, physical exams, blood draws, CT scans, and follow-up will be performed at VA Greater Los Angeles. All interventional procedures including leukapheresis, CT guided/bronchoscopic biopsies and vaccine injections will be performed at University of California Los Angeles (UCLA).

* Adults over the age of 21 capable of giving informed consent
* Pathologically confirmed non-small cell lung cancer (NSCLC)
* Stage IIIB, IV or recurrent disease
* Progressive disease despite one or more prior chemotherapy regimens as standard of care OR patient refusal of standard chemotherapy
* Measurable metastatic disease by RECIST guidelines
* Patients with a major endobronchial lesion in the segmental, lobar, or mainstem bronchus with complete obstruction of the airway may be eligible for bronchoscopic injection provided there is no evidence of respiratory failure (defined as SaO2 at least 90% on room air, PCO2 less than, or equal to 45 mm Hg, or FEV1 greater than 1.0L)
* Patients with an endobronchial lesion in the segmental bronchus with variable stenosis (not completely obstructed) and not amenable to standard palliative airway treatments (i.e., laser and stenting) may be eligible for bronchoscopic injection if there is no indication of respiratory failure as defined above
* Patient with bullous disease may undergo CT-guided transthoracic injection provided the targeted tumor has an intended needle path without crossing bullae
* ECOG performance status 0-2
* BUN less than or equal to 40 OR serum creatinine less than 2 Serum total bilirubin less than or equal to 1.5 OR serum transaminases less than or equal to 2.5 times upper limit of normal (ULN)
* Negative pregnancy test (if applicable)
* Fertile patients must use effective contraception
* More than 14 days since prior acute therapy for viral, bacterial, or fungal infections
* More than 30 days since prior and no concurrent corticosteroids
* More than 15 days since prior radiotherapy
* More than 30 days since prior chemotherapy, or non-cytotoxic investigational agents

Exclusion Criteria

* Active CNS metastases (i.e., progression of CNS disease during the past 30 days without intervention)
* Evidence of coagulopathy, defined as PT and/or PTT more than 1.5 times ULN or platelets more than or equal to 100,000/mm3.
* Evidence of leukoplakia, defined as absolute neutrophil count more than or equal to 1,500/mm3
* Evidence of respiratory failure (defined as SaO2 less than 90% on room air, PCO2 more than 45 mm Hg, or FEV1 less than 1.0 L
* NYHA class III-IV within the past year
* Myocardial infarction within the past year
* Comorbid disease or medical condition that would impair the ability of the patient to receive or comply with the study protocol
* Acute viral, bacterial or fungal infection that requires specific therapy
* HIV positive
* Hypersensitivity to any reagents used in the study
* Signs or sensitivity of acute adenoviral infection (i.e., conjunctivitis or documented adenoviral upper respiratory infection)
* Pregnant or nursing
* Prior organ allograft

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No